In the case of both benzbromarone and niclosamide, repurposing of these agents as inhibitors of TMEM16A for the treatment of pulmonary hypertension and respiratory diseases have been proposed and clinical studies performed (Cabrita et al., 2019; Miner et al., 2019; Papp et al., 2019; Singh et al., 2022). Here, ANO1 is linked to respiratory system disorder.